author-photo

Neil A. OBrien

University of California, Los Angeles

4

Papers

21

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

EMP2 is a novel regulator of stemness in breast cancer cells.

2020 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)
Abstract 4124: The combination of PARP inhibitor talazoparib with low-dose temozolomide results in increased cell lethality in BRCA1/2 wild-type melanoma, small cell lung cancer, ovarian, and colon cancer cell lines and mouse xenografts via the formation of DNA double-strand breaks during S-phase

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.

2020 Breast Cancer Research
Show All
- Source
- Cite
- Save
Citations (19)
Abstract 5640: Targeting tumor-promoting inflammation (TPI) via the IL-1βpathway for cancer immunotherapy

2020 Immunology
Show All
- Source
- Cite
- Save
Citations (0)